|  |
| --- |
| **Supplemental Digital Content, Table 3.** **Neuromuscular Blockade Reversal Utilization and Monitoring** |
| Parameter | Primary Survey | Secondary Survey | *P* |
| Reversal Agent(s) Used in Pediatric Practice | SugamNeostigmineBoth Sugam and NeostigmineNo Reversal Used | 106 (25.3%)181 (43.2%)111 (26.5%)21 (5.0%) | 16 (21.3%)30 (40.0%)28 (37.3%)1 (1.3%) | 0.19 |
| If Both Utilized, FrequencySugam Used | Mostly (50% - 100%)Sometimes (25% - 50%)Rarely (>0% - 25%) | 57 (51.4%)46 (41.4%)8 (7.2%) | 17 (56.7%)11 (36.7%)2 (6.7%) | 0.90 |
| Institutional Restriction on Reversal Agent(s) | Sugam OnlyNeostigmine OnlyBothNone | 19 (4.8%)0 (0.0%)47 (11.8%)332 (83.4%) | 4 (5.3%)0 (0.0%)8 (10.7%)63 (84.0%) | 0.93 |
| Voluntary Personal Restriction of Reversal Agent(s) Due to Cost or Efficacy | Sugam – Too CostlyNeostigmine – Too CostlySugam – Less EffectiveNeostigmine – Less EffectiveNone | 99 (24.9%)\*5 (1.3%)\*13 (3.3%)\*108 (27.1%)\*199 (50.0%)\* | 14 (18.7%)1 (1.3%)2 (2.6%)14 (18.7%)44 (58.7%) | 0.41 |
| Patient Age Restrictions for Sugam Administration | No Age Restriction<1 Month Old<2 Months Old<2 Years Old<12 Years Old12 Years Old to <18 Years Old | 243 (61.1%)\*36 (9.0%)\*37 (9.3%)\*41 (10.3%)\*21 (5.3%)\*46 (11.6%)\* | 42 (56.0%)7 (9.3%)7 (9.3%)6 (8.0%)4 (5.3%)9 (12.0%) | 0.99 |
| TOF Monitor Use Since Sugam Introduction | No Longer a NeedStill Routinely UseCase-by-Case BasisNever Monitored Before | 6 (1.7%)231 (67.0%)103 (29.9%)5 (1.4%) | 0 (0.0%)43 (57.3%)31 (41.3%)1 (1.3%) | 0.20 |

Data are presented as count (percentage). Analysis was performed with the Fisher exact test. P < 0.05 was considered statistically significant. Abbreviations: Sugam = Sugammadex, TOF = Train of Four.

\*Because multiple answers were accepted, percentages do not equal 100%.